# US 2021/0275650 A1 · Inducible regulatory t-cell generation for hematopoietic transplants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275650 A1
- Document ID: US20210275650A1
- Status: Published application
- Kind: A1
- Application number: 17/133,702
- Filed: 2020-12-24
- Published: 2021-09-09
- Earliest claimed: 2008-06-19
- Assignees: The Trustees of the University of Pennsylvania; Regents of the University of Minnesota
- Applicants: The Trustees of the University of Pennsylvania; Regents of the University of Minnesota
- Inventors: James L. Riley; Carl H. June; Bruce R. Blazar; Keli Hippen
- Web page: https://patentgrep.com/patent/US20210275650A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/42: Cancer antigens
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/70: Enzymes
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.

## Claims

### Claim 1

A method for inhibiting cytotoxic T-lymphocyte (CTL) activity, the method comprising contacting a cytotoxic T-lymphocyte with an effective amount of iTregs.

### Claim 2

A method for generating an immunosuppressive effect in a mammal having an alloresponse or autoimmune response, the method comprising administering to said mammal an effective amount of iTregs.

### Claim 3 (depends on 2)

The method of claim 2, wherein said mammal having an alloresponse or autoimmune response follows tissue transplantation, and wherein the method further comprises suppressing, blocking or inhibiting graft-vs-host disease in the mammal.

### Claim 4 (depends on 2)

The method of claim 2, wherein said mammal is a human.

### Claim 5

A method for preventing an alloresponse or an autoimmune response in a mammal, said method comprising administering to said mammal, prior to onset of an alloresponse or autoimmune response, an effective amount of iTreg to prevent said response.

### Claim 6 (depends on 5)

The method of claim 5, wherein said mammal is treated prior to, at the time of, or immediately after tissue transplantation, and wherein the method further comprises preventing onset of graft-vs-host disease in said mammal.

### Claim 7 (depends on 6)

The method of claim 6, wherein said mammal is treated prior to, at the time of, or immediately after tissue transplantation, and wherein the method further comprises blocking rejection of the transplanted tissue in the mammal.

### Claim 8 (depends on 5)

The method of claim 5, wherein said mammal is a human.

### Claim 9

A method of treating a transplant recipient to reduce in said recipient an immune response against the transplant, the method comprising administering to a transplant recipient, an effective amount of iTregs to reduce an immune response against the antigen.

### Claim 10 (depends on 9)

The method of claim 9, further comprising administering to said recipient an immunosuppressive agent.

### Claim 11 (depends on 9)

The method of claim 9, wherein said iTregs are administered to the recipient prior to said transplant, concurrently with said transplant, or subsequent to the transplantation of the transplant.

### Claim 12 (depends on 1)

The method of claim 1, wherein said iTregs are generated by isolating a non-Treg from peripheral blood, wherein said non-Treg is selected from the group consisting of a CD4+ cell, a CD4+CD25− cell, and a CD4+CD25−CD45RA+ cell;
contacting the non-Treg with an agent capable of converting said non-Treg into an iTreg, wherein said agent is selected from the group consisting of a breakdown product of tryptophan, an analog of a metabolic breakdown product of tryptophan, a histone deacetylase inhibitor (HDACi), an mTOR inhibitor, and any combination thereof;
contacting the iTreg with a mTOR inhibitor, wherein the mTOR inhibitor inhibits non-Treg growth and is selected from the group consisting of tacrolimus, rapamycin, rapamycin derivative, and any combination thereof; and
costimulating the iTreg with anti-CD3 antibody and anti-CD28 antibody, wherein said iTreg is immunosuppressive, and the iTreg is expanded.

### Claim 13 (depends on 2)

The method of claim 2, wherein said iTregs are generated by isolating a non-Treg from peripheral blood, wherein said non-Treg is selected from the group consisting of a CD4+ cell, a CD4+CD25− cell, and a CD4+CD25−CD45RA+ cell;
contacting the non-Treg with an agent capable of converting said non-Treg into an iTreg, wherein said agent is selected from the group consisting of a breakdown product of tryptophan, an analog of a metabolic breakdown product of tryptophan, a histone deacetylase inhibitor (HDACi), an mTOR inhibitor, and any combination thereof;
contacting the iTreg with a mTOR inhibitor, wherein the mTOR inhibitor inhibits non-Treg growth and is selected from the group consisting of tacrolimus, rapamycin, rapamycin derivative, and any combination thereof; and
costimulating the iTreg with anti-CD3 antibody and anti-CD28 antibody, wherein said iTreg is immunosuppressive, and the iTreg is expanded.

### Claim 14 (depends on 5)

The method of claim 5, wherein said iTregs are generated by isolating a non-Treg from peripheral blood, wherein said non-Treg is selected from the group consisting of a CD4+cell, a CD4+CD25− cell, and a CD4+CD25−CD45RA+ cell;
contacting the non-Treg with an agent capable of converting said non-Treg into an iTreg, wherein said agent is selected from the group consisting of a breakdown product of tryptophan, an analog of a metabolic breakdown product of tryptophan, a histone deacetylase inhibitor (HDACi), an mTOR inhibitor, and any combination thereof;
contacting the iTreg with a mTOR inhibitor, wherein the mTOR inhibitor inhibits non-Treg growth and is selected from the group consisting of tacrolimus, rapamycin, rapamycin derivative, and any combination thereof; and
costimulating the iTreg with anti-CD3 antibody and anti-CD28 antibody, wherein said iTreg is immunosuppressive, and the iTreg is expanded.

### Claim 15 (depends on 9)

The method of claim 9, wherein said iTregs are generated by isolating a non-Treg from peripheral blood, wherein said non-Treg is selected from the group consisting of a CD4+ cell, a CD4+CD25− cell, and a CD4+CD25−CD45RA+ cell;
contacting the non-Treg with an agent capable of converting said non-Treg into an iTreg, wherein said agent is selected from the group consisting of a breakdown product of tryptophan, an analog of a metabolic breakdown product of tryptophan, a histone deacetylase inhibitor (HDACi), an mTOR inhibitor, and any combination thereof;
contacting the iTreg with a mTOR inhibitor, wherein the mTOR inhibitor inhibits non-Treg growth and is selected from the group consisting of tacrolimus, rapamycin, rapamycin derivative, and any combination thereof; and
costimulating the iTreg with anti-CD3 antibody and anti-CD28 antibody, wherein said iTreg is immunosuppressive, and the iTreg is expanded.
